Back to Agenda
SESSION 10: BENEFIT-RISK MANAGEMENT PLAN – CASE STUDIES
Session Chair(s)
Jan Petracek, MD, MSc
CEO, iVigee Services a.s., Czech Republic
- Small molecules and generics
- Biologics and biosimilars
- Advanced therapies
- Combination therapies
Speaker(s)
Small Molecule Group Work
Michael Von Forstner, PhD, MPH, MSc
Chief Science Officer, MedGenie AG, Switzerland
Combination Product Group Work
Jan Petracek, MD, MSc
CEO, iVigee Services a.s., Czech Republic
Biologic Group Work
Jan Petracek, MD, MSc
CEO, iVigee Services a.s., Czech Republic
Advanced Therapies Group Work
Jan Petracek, MD, MSc
CEO, iVigee Services a.s., Czech Republic
Have an account?